- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at upcoming scientific conferences
Scheduled conference presentations in May include the following:
15th Annual North American TIDES Conference - Boston, MA, USA, May 12-15, 2013
May 14, 2013 - An oral presentation titled, "Development of DPC Technology for Therapeutic siRNA Delivery," will be presented by David Lewis, Ph.D., Vice President, Biology;
May 15, 2013 - An oral presentation titled, "Co-injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Small Interfering RNA-Conjugates In Vivo," will be presented by David B. Rozema, Ph.D., Vice President, Chemistry;
Digestive Disease Week 2013 - Orlando, FL, USA, May 18-21, 2013
May 18, 2013 - A poster presentation titled, "Long duration of effect from an RNAi therapeutic to treat chronic hepatitis B virus infection correlates with persistence of the phosphorylated guide strand," will be presented by Christine Wooddell, Ph.D., Senior Scientist.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to
For more information, please click here
The Trout Group, LLC
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016